In a landmark analysis, investigators of the Multicentric Italian Lung Detection (MILD) trial have confirmed 10-year mortality reductions with lung cancer screening using low-dose helical CT (LDCT). These data complement the reduced lung cancer-specific mortality reported in the National Lung Screening Trial and reinforce the rationale for broad implementation of LDCT screening in high-risk populations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China
Scientific Reports Open Access 25 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
US Preventive Services Task Force. Lung cancer: screening. Recommendation summary. USPSTF https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening (2013).
Centers for Medicare & Medicard Services. Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). CMS https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274 (2015).
De Koning, H. et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial [abstract]. J. Thorac. Oncol. 13, S185 (2018).
Silva, M., Pastorino, U. & Sverzellati, N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin. Radiol. 72, 389–400 (2017).
Pastorino, U. et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann. Oncol. https://doi.org/10.1093/annonc/mdz117 (2019).
Pastorino, U. et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 21, 308–315 (2012).
Heleno, B., Siersma, V. & Brodersen, J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening: a secondary analysis of the Danish Lung Cancer Screening Trial. JAMA Intern. Med. 178, 1420–1422 (2018).
Kovalchik, S. A. et al. Targeting of low-dose CT screening according to the risk of lung cancer death. N. Engl. J. Med. 369, 245–254 (2013).
Schabath, M. B. et al. Differences in patient outcomes of prevalence, interval, and screen-detected lung cancers in the CT arm of the national lung screening trial. PLOS ONE 11, e0159880 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Schabath, M.B., Aberle, D.R. MILD trial, strong confirmation of lung cancer screening efficacy. Nat Rev Clin Oncol 16, 529–530 (2019). https://doi.org/10.1038/s41571-019-0231-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0231-3
This article is cited by
-
Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China
Scientific Reports (2021)
